Objective: As APS (antiphospholipid syndrome) can be either primary or secondary to a wide range of other conditions (such as autoimmune diseases, malignancies, infectious diseases, and drug-induced conditions) the aim of this study was to describe a novel overlap syndrome of APS. Methods: All patients diagnosed with either PM (polymytosis) or DM (dermatomytosis) who were treated in the Rheumatology Unit, Sheba Medical Center, were followed-up in the past 8 years for the appearance of a clinical manifestation of the APS, and conversely, patients with APS treated by us were clinically assessed for the presence of signs and symptoms of PM and DM. Both conditions were diagnosed according to accepted diagnostic criteria.
Results: Three patients were found to have both APS and PM/DM. A patient with PM had transverse myelopathy, a patient with DM had pulmonary embolism, and a patient with PM had recurrent abortions, stroke, livedo reticularis and mitral regurgitation. Both patients with PM had also SLE (systemic lupus erythematosis).
Conclusions: APS can be associated with a wide range of diseases. Future data would reveal which therapy is the best for the association of PM/DM with APS, and determine the pathogenesis and prognosis in patients with this association.
Sherer Y , Blank M , Shoenfeld Y . Immunomodulation of experimental antiphospholipid syndrome . Scand J Rheumatol1998; 27 Suppl 1: 48–52 .
2.
Asherson RA , Cervera R , Pitte JC , Shoenfeld Y . The antiphospholipid syndrome: history, definition, classification and differential diagnosis. In: Asherson RA , Cervera R , Pitte JC and Shoenfeld Y (eds). The Antiphospholipid Syndrome. CRC Press; Boca Raton , 1996, pp 3–12.
3.
Asherson RA , Cervera R . ‘Primary’, ‘secondary’ and other variants of the antiphospholipid syndrome . Lupus1994; 3: 293–298 .
4.
Maugars YM , Berthelot JMM , Abbas AA et al. Long-term prognosis of 69 patients with dermatomyositis or polymyositis . Clin Exp Rheum1996; 14: 263–274 .
5.
Maoz CR , Langevitz P , Livneh A et al. High incidence of malignancies in patients with dermatomyositis and polymyositis: an 11-year analysis . Semin Arthritis Rheum1998; 27: 319–324 .
6.
Tomer Y , Sherer Y , Shoenfeld Y . Autoantibodies, autoimmunity and cancer . Oncol Rep1998; 5: 753–761 .
Tanimoto K , Nakano K , Kano S et al. Classification criteria for polymyositis and dermatomyositis . J Rheumatol1995; 22: 668–674 .
9.
Bohan A , Peter JB . Polymyositis and dermatomyositis . N Engl J Med1975; 292: 344–347 .
10.
Khamashta MA , Hughes GRV . Phospholipid autoantibodies-Cardiolipin. In: Peter JB and Shoenfeld Y (eds). Autoantibodies. Elsevier: Amsterdam , 1996, pp 624–629.
11.
Tan EM , Cohen AS , Fries JF et al. The 1982 revised criteria for the classification of systemic lupus erythematosus . Arthritis Rheum1982; 25: 1271–1277 .
12.
Lavalle C , Pizarro S , Drenkard C et al. Transverse myelitis: manifestation of systemic lupus erythematosus strongly associated with antiphospholipid antibodies . J Rheumatol1990; 17: 34–37 .
13.
Chang R , Quismorio P Jr.Transverse myelopathy in systemic lupus erythematosus (SLE) . Arthritis Rheum1990; 33Suppl 9: S102-S102 .
14.
Font J , Lopez-Soto A , Cervera R et al. The ‘primary’ antiphospholipid syndrome: antiphospholipid antibody pattern and clinical features of a series of 23 patients . Autoimmunity1991; 9: 69–75 .
15.
Boey ML , Colaco CB , Gharavi AE et al. Thrombosis in systemic lupus erythematosus: striking association with the presence of circulating lupus anticoagulant . BrMJ1983; 287: 1021–1023 .
16.
Shoenfeld Y , Sherer Y , Blank M . Antiphospholipid syndrome in pregnancy—animal models and clinical implications . Scand J Rheumatol1998; 27 Suppl 1: 33–36 .
17.
Cohen J , Bakimer R , Shoenfeld Y . Fecundity in autoimmune diseases . Early Preg: Biol Med1995; 1: 93–105 .
18.
Harris EN , Gharavi AE , Asherson RA et al. Cerebral infarction in systemic lupus: association with anticardiolipin antibodies . Clin Exp Rheumatol1984; 25: 1271–1277 .
19.
The Antiphospholipid Antibodies in Stroke Study Group (APASS) . Anticardiolipin antibodies are an independent risk factor for first ischemic stroke . Neurology1993; 43: 2069–2073 .
20.
Brey RL , Escalante A , Futrell N , Asherson RA . Cerebral thrombosis and other neurological manifestations in the antiphospholipid syndrome. In: Asherson RA , Cervera R , Piette JC and Shoenfeld Y (eds). The Antiphospholipid Syndrome. CRC Press: Boca Raton , 1996; pp 133–150.
21.
Huemer C , Duesse M , Seerainer W , Lubec G . Juvenile dermatomyositis with major thrombosis—an unusual course . Clin Exp Rheumatol1995; 13: 795-795 (letter).
22.
Jackson J , McDonald M , Casey E et al. Mixed connective tissue disease with arterial thrombosis, antiphospholipid antibodies and heparin induced thrombocytopenia . J Rheumatol1990; 17: 1523–1524 .
23.
Perinbasekar S , Chawla K , Rosner F , Depestre M . Complete recovery from renal infarcts in a patient with mixed connective tissue disease . Am J Kidney Dis1995; 26: 649–653 .
24.
Zuber M , Kranzhofer N , Lindemuth R , Hartmann F . A patient with mixed collagen disease, antiphospholipid syndrome and Sjogren syndrome . Med Klin1998; 93: 34–38 .
25.
Katayama I , Otoyama K , Kondo S et al. Clinical manifestations in anticardiolipin antibody-positive patients with progressive systemic sclerosis . J Am Acad Dermatol1990; 23: 198–201 .
26.
Frances C , Bletry O , Piette JC . Dermatologic manifestations in the antiphospholipid syndrome. In: Asherson RA , Cervera R , Piette JC and Shoenfeld Y (eds). The Antiphospholipid Syndrome. CRC Press: Boca Raton , 1996, pp 201–211.
27.
von Muhlen CA , Tan EM . Autoantibodies in the diagnosis of systemic rheumatic diseases . Semin Arthritis Rheum1995; 24: 323–358 .
28.
Merkel PA , Chang Y , Pierangeli SS et al. The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases . Am J Med1996; 101: 576–583 .
29.
Crowson AN , Magro CM . The role of microvascular injury in the pathogenesis of lesions of dermatomyositis . Hum Pathol1996; 27: 15–19 .
30.
Krause I , Blank M , Kopolovic J et al. Abrogation of experimental systemic lupus erythematosus and primary antiphospholipid syndrome with intravenous gamma globulin . J Rheumatol1995; 22: 1068–1074 .
31.
Bakimer R , Guilburd B , Zurgil N , Shoenfeld Y . The effect of intravenous g-globulin on the induction of experimental antiphospholipid syndrome . Clin Immunol Immunopathol1993; 69: 97–102 .
32.
Sherer Y , Shoenfeld Y . The antiphospholipid syndrome—an entity to be expanded . Am J Reprod Immunol1999; 41: 113–116 .
